Jasper Therapeutics (JSPR) Other Non-Current Assets (2020 - 2025)
Jasper Therapeutics (JSPR) posted quarterly Other Non-Current Assets of $417000.0 for Q4 2025, little changed year-over-year from $417000.0 in Q4 2024, and up 178.0% quarter-over-quarter from $150000.0 in Q3 2025.
Jasper Therapeutics (JSPR) Other Non-Current Assets (2020 - 2025) Analysis & Trends
Jasper Therapeutics' Other Non-Current Assets history runs 6 years deep, the most recent figure standing at $417000.0 for Q4 2025.
- In Q4 2025, Other Non-Current Assets changed 0.0% year-over-year to $417000.0; the TTM figure through Dec 2025 stood at $417000.0 (changed 0.0% YoY), while the FY2025 annual figure was $417000.0, changed 0.0% from the prior year.
- Other Non-Current Assets for Q4 2025 stood at $417000.0, up from $150000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $2.5 million in Q2 2022, with the low at $150000.0 in Q3 2025.
- The 5-year median for Other Non-Current Assets is $417000.0 (2022), against an average of $624111.1.
- The sharpest annual moves came in 2023 and 2025: Other Non-Current Assets jumped 222.06% in 2023, then sank 83.49% in 2025.
- Jasper Therapeutics' Other Non-Current Assets stood at $645000.0 in 2021, then sank by 35.35% to $417000.0 in 2022, then surged by 222.06% to $1.3 million in 2023, then sank by 68.95% to $417000.0 in 2024, then changed by 0.0% to $417000.0 in 2025.
- Business Quant data shows JSPR's Other Non-Current Assets at $417000.0 in Q4 2025, $150000.0 in Q3 2025, and $192000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 62.96 Mn |
| 10 | Jasper Therapeutics | 20.09 Mn | 20.09 Mn | - | 43,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 417,000.00 |
| Sep 30, 2025 | 150,000.00 |
| Jun 30, 2025 | 192,000.00 |
| Mar 31, 2025 | 532,000.00 |
| Dec 31, 2024 | 417,000.00 |
| Sep 30, 2024 | 417,000.00 |
| Jun 30, 2024 | 1.16 Mn |
| Mar 31, 2024 | 417,000.00 |
| Dec 31, 2023 | 1.34 Mn |
| Sep 30, 2023 | 417,000.00 |
| Jun 30, 2023 | 445,000.00 |
| Mar 31, 2023 | 417,000.00 |
| Dec 31, 2022 | 417,000.00 |
| Sep 30, 2022 | 417,000.00 |
| Jun 30, 2022 | 2.47 Mn |
| Mar 31, 2022 | 611,000.00 |
| Dec 31, 2021 | 645,000.00 |
| Sep 30, 2021 | 345,000.00 |
| Dec 31, 2020 | 345,000.00 |